Undisclosed RLT Program(s)
Oncology
Key Facts
About Actithera
Actithera is an emerging radiopharmaceutical company leveraging a proprietary chemistry platform to design novel radioligand therapies (RLTs) with prolonged tumor retention. Its core strategy involves using covalent chemistries to create irreversible bonds with tumor-associated proteins, aiming to deliver more effective radiation with fewer treatment cycles and reduced toxicity. Founded by CEO Andreas Goutopoulos and backed by a syndicate of European life science venture capital firms, the company is in the preclinical stage, advancing its platform towards clinical development for cancers with high unmet need. Actithera's approach is isotope-agnostic, allowing flexibility in pairing radionuclides with targeting molecules based on tumor biology.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |